Search

Displaying results 3451 - 3460 of 10000 in total
  1. Drug

    Lapyrium

    go.drugbank.com/drugs/DB09376
    Approved

    Lapyrium is a quaternary ammonium cation used as a surfactant, antistatic agent, and biocide in various cosmetic products [A19426]. It is commonly found formulated as lapyrium chloride.

  2. Drug

    Sitaxentan

    go.drugbank.com/drugs/DB06268
    ApprovedWithdrawn

    Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Inhibitors
  3. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    many as 40% of patients will experience relapsed or refractory disease. … It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.

  4. Drug

    Mephenesin

    go.drugbank.com/drugs/DB13583
    ApprovedWithdrawn

    Mephenesin is a synthetic cresol glyceryl ether which produces transient muscle relaxation and paralysis via central nervous system depression . It first entered use in the 1950s.

  5. Drug

    LCP-AtorFen

    go.drugbank.com/drugs/DB05769
    Investigational

    treatment of high cholesterol levels, addressing three primary cardiovascular risk factors: low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and triglycerides (TG

  6. Drug

    Landiolol

    go.drugbank.com/drugs/DB12212
    ApprovedInvestigational

    [A264733] Compared to other beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity … [A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  7. Drug

    Drozitumab

    go.drugbank.com/drugs/DB19106
    Investigational

    Drozitumab is a human monoclonal antibody directed against tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), a member of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) … It was developed by Genentech as a drug for the treatment of cancers

    Synonyms: Immunoglobulin g1, anti-(human citokine receptor dr5 (death receptor 5)) (human monoclonal heavy chain), disulfide with human l3-chain, dimer
  8. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  9. Drug

    Epratuzumab

    go.drugbank.com/drugs/DB04958
    Investigational

    This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.

  10. Drug

    NCX 950

    go.drugbank.com/drugs/DB05849
    Experimental

    NCX 950, beta2-adrenoceptor agonists is widely used in the treatment of pulmonary diseases.